CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 74 enrolled
Drug / intervention
Deucravacitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04857034
NCT04857034Phase 2Active
CompareCT.gov

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Bristol-Myers Squibb·interventional·Posted Apr 23, 2021·Updated Sep 10, 2025

In Brief

A Phase 2 clinical trial evaluating Deucravacitinib and Placebo for Lupus Erythematosus, Discoid and Lupus Erythematosus, Subacute Cutaneous. Active but no longer recruiting, targeting 74 participants across 41 sites in 8 countries.

Detailed Summary

The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
CountriesArgentina, Australia, France, Germany, Mexico, Poland, Taiwan, United States
Collaborators--

Timeline

Phase 2Active
2022202320242025202620272028
First PostedApr 23, 2021
Enrollment StartJul 12, 2021
Primary CompletionAug 22, 2024
Study CompletionFeb 28, 2028
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.2 years ago

Interventions

Deucravacitinibdrug

Specified dose on specified days

Placebodrug

Specified dose on specified days